An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Company News

Company News

Brexpiprazole: A Third-Generation Antipsychotic

Time:2025-04-23 Views:4

  Brexpiprazole, an atypical antipsychotic, exerts its therapeutic effects through a ​​triple mechanism​​ combining ​​partial agonism at dopamine D2 (Ki=0.30 nM) and serotonin 5-HT1A receptors (Ki=0.12 nM)​​ with ​​antagonism at 5-HT2A receptors​​. This unique receptor profile enables comprehensive improvement in positive/negative symptoms, cognitive dysfunction, and affective symptoms in schizophrenia. Notably, it is the only antipsychotic in a ​​_Lancet_​​ meta-analysis of 32 antipsychotics to demonstrate ​​no statistically significant difference in all-side-effect risks compared to placebo​​.


  In 2015, the FDA approved brexpiprazole for the adjunctive treatment of schizophrenia and depression; 2018: brexpiprazole launched in the EU and Japan; 2023: FDA expands indication to Alzheimer‘s disease Treatment of agitation, PTSD, and borderline personality disorder in patients with Alzheimer‘s disease.June 2024 Brexpiprazole was approved for marketing by  NMPA (trade name: Rexulti®) The patent for brexpiprazole‘s core compound expires in 2026, and more than thirty domestic pharmaceutical companies have already submitted applications for generic marketing.


  In its actual production process, it will involve a variety of brexpiprazole impurities and related research and analysis, some of the impurities are known to include: brexpiprazole impurity 1--50, brexpiprazole sulfoxide, structural warning impurity brexpiprazole nitrogen oxides and so on.

  For the needs of pharmaceutical enterprises and quality control, SZEB supplies a suite of Brexpiprazole impurities in stock, providing COA, HPLC/HNMR/mass spectrometry analysis (in line with USP/EP standards), while supporting the structure of nitrosamines, genotoxic impurities + content calibration. One-stop service. For more details, please visit
the official website:
https://www.ex-biotech.com/  
inquiry hotline: 0755-23051186.




  • Previous:Nothing
  • Next:Abemaciclib impurities  2025/04/18